LYRA

Company Overview — What Does Lyra Therapeutics, Inc. Do?

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Lyra Therapeutics, Inc. (LYRA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Maria Palasis and employs approximately 50 people. With a market capitalization of $2M, LYRA is one of the notable companies in the Healthcare sector.

Lyra Therapeutics, Inc. (LYRA) Stock Rating — Reduce (April 2026)

As of April 2026, Lyra Therapeutics, Inc. receives a Reduce rating with a composite score of 29.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LYRA ranks #3,520 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Lyra Therapeutics, Inc. ranks #549 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LYRA Stock Price and 52-Week Range

Lyra Therapeutics, Inc. (LYRA) currently trades at $0.65. The stock gained $0.12 (22.6%) in the most recent trading session. The 52-week high for LYRA is $37.50, which means the stock is currently trading -98.3% from its annual peak. The 52-week low is $0.08, putting the stock 692.7% above its annual trough. Recent trading volume was 24K shares, suggesting relatively thin trading activity.

Is LYRA Overvalued or Undervalued? — Valuation Analysis

Lyra Therapeutics, Inc. (LYRA) carries a value factor score of 6/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 4.00x, compared to 1.66x for the average Healthcare stock.

At current multiples, Lyra Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Lyra Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Lyra Therapeutics, Inc. (LYRA) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -404.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -93.7% versus the sector average of -33.1%.

On a margin basis, Lyra Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -10245.7% (sector: -66.1%). Net profit margin stands at -9689.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -95.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LYRA Debt, Balance Sheet, and Financial Health

Lyra Therapeutics, Inc. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.71x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $22M.

LYRA has a beta of -7.57, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Lyra Therapeutics, Inc. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Lyra Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Lyra Therapeutics, Inc. reported revenue of $586,000 and earnings per share (EPS) of $-18.62. Net income for the quarter was $-34M. Gross margin was 100.0%. Operating income came in at $-36M.

In FY 2025, Lyra Therapeutics, Inc. reported revenue of $398,000 and earnings per share (EPS) of $-18.62. Net income for the quarter was $-29M. Revenue grew -74.1% year-over-year compared to FY 2024. Operating income came in at $-31M.

In Q3 2025, Lyra Therapeutics, Inc. reported revenue of $25,000 and earnings per share (EPS) of $-3.38. Net income for the quarter was $-6M. Revenue grew -87.2% year-over-year compared to Q3 2024. Operating income came in at $-6M.

In Q2 2025, Lyra Therapeutics, Inc. reported revenue of $183,000 and earnings per share (EPS) of $-5.51. Net income for the quarter was $-7M. Revenue grew -69.4% year-over-year compared to Q2 2024. Operating income came in at $-9M.

Over the past 8 quarters, Lyra Therapeutics, Inc. has experienced revenue contraction from $598,000 to $586,000. Investors analyzing LYRA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LYRA Dividend Yield and Income Analysis

Lyra Therapeutics, Inc. (LYRA) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LYRA Momentum and Technical Analysis Profile

Lyra Therapeutics, Inc. (LYRA) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

LYRA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Lyra Therapeutics, Inc. (LYRA) ranks #549 out of 838 stocks based on the Blank Capital composite score. This places LYRA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LYRA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LYRA vs S&P 500 (SPY) comparison to assess how Lyra Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

LYRA Next Earnings Date

No upcoming earnings date has been announced for Lyra Therapeutics, Inc. (LYRA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LYRA? — Investment Thesis Summary

The quantitative profile for Lyra Therapeutics, Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 6/100 indicates premium valuation. High volatility (stability score 25/100) increases portfolio risk.

In summary, Lyra Therapeutics, Inc. (LYRA) earns a Reduce rating with a composite score of 29.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LYRA stock.

Related Resources for LYRA Investors

Explore more research and tools: LYRA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LYRA head-to-head with peers: LYRA vs AZN, LYRA vs SLGL, LYRA vs VMD.